Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Eyeing 2016 Revenues of $14.5B to $15.5B

NEW YORK (GenomeWeb News) – Based on expectations of mid-single digit organic revenue growth annually, Thermo Fisher Scientific's revenues for 2016 could fall between $14.5 billion and $15.5 billion, the company said in a presentation at its analyst meeting today.

In the presentation, the Waltham, Mass.-based company added that adjusted EPS for 2016 is expected to fall in the $7.50 to $8.75 range with free-cash flow of between $2.2 billion and $2.5 billion.

The estimates are based on a long-term model the firm is using that calls for low to mid-teen annual growth for its adjusted EPS.

In February, Thermo Fisher reported $11.73 billion in revenues for full-year 2011, an 11 percent increase from $10.57 billion in 2010. Its 2011 net income was $1.33 billion, or $3.46 per share.

Thermo Fisher also said that it plans to ramp up its presence in Asia-Pacific and the emerging markets. Last year, about 19 percent of its business came from the APAC and emerging markets. By 2016, it has a goal of increasing that figure to 25 percent with a strategy that seeks to replicate a "successful China/India formula" in other countries, such as South Korea, Taiwan, Brazil, and Russia.

It will expand its manufacturing footprint to serve local markets and capitalize on a "huge demand" for specialty diagnostics, Thermo Fisher said.

The firm reiterated its FY 2012 guidance for revenues between $12.27 billion and $12.43 billion, and adjusted EPS between $4.71 and $4.83. The current consensus Wall Street estimates are revenues of $12.42 billion and adjusted EPS of $4.80.

In Wednesday morning trade on the New York Stock Exchange shares of Thermo Fisher were down a little more than 2 percent at $50.11.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.